Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Merck & Co. Inc.
IndexDJIA S&P500 P/E32.74 EPS (ttm)1.82 Insider Own0.04% Shs Outstand2.85B Perf Week3.22%
Market Cap169.85B Forward P/E16.73 EPS next Y3.56 Insider Trans-1.04% Shs Float2.85B Perf Month0.66%
Income5.39B PEG4.89 EPS next Q0.86 Inst Own75.20% Short Float0.74% Perf Quarter-0.91%
Sales43.08B P/S3.94 EPS this Y-26.50% Inst Trans-1.67% Short Ratio1.85 Perf Half Y3.37%
Book/sh15.71 P/B3.79 EPS next Y2.12% ROA5.20% Target Price63.92 Perf Year25.86%
Cash/sh5.03 P/C11.84 EPS next 5Y6.70% ROE11.10% 52W Range47.19 - 61.74 Perf YTD22.67%
Dividend1.80 P/FCF30.21 EPS past 5Y-16.50% ROI6.60% 52W High-4.80% Beta0.34
Dividend %3.02% Quick Ratio1.10 Sales past 5Y13.00% Gross Margin59.70% 52W Low24.55% ATR1.11
Employees77300 Current Ratio1.30 Sales Q/Q-4.30% Oper. Margin18.10% RSI (14)50.60 Volatility2.02% 1.69%
OptionableYes Debt/Eq0.62 EPS Q/Q-18.40% Profit Margin12.50% Rel Volume0.69 Prev Close59.58
ShortableYes LT Debt/Eq0.41 EarningsOct 27 BMO Payout94.60% Avg Volume11.30M Price58.78
Recom2.50 SMA20-0.86% SMA501.35% SMA2002.84% Volume6,059,365 Change-1.35%
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Feb-04-11Reiterated UBS Buy $42 → $40
Jan-24-11Reiterated Deutsche Bank Buy $48 → $43
Jan-24-11Reiterated Barclays Capital Overweight $43 → $41
Dec-22-14 11:44AM  Merck Finally Gets Some Good News on Cubist at The Wall Street Journal
10:34AM  Stocks Struggle To Hold Gains; Alaska Air, Spirit Up at Investor's Business Daily
09:32AM  NewLink Genetics Surges 3% Following Ebola Contract News Benzinga
08:00AM  NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award GlobeNewswire
Dec-19-14 07:06PM  [$$] FDA Approves Cubist's Experimental Antibiotic Zerbaxa at The Wall Street Journal
06:34PM  FDA OKs Cubist antibiotic for serious infections AP
06:30PM  FDA Approves Second Cubist Antibiotic Of 2014 at Forbes
08:00AM  Merck Begins Tender Offer to Acquire Cubist Business Wire
06:49AM  The Ebola Treatment You Haven't Heard Of at Forbes
Dec-18-14 02:26PM  Cardiology Drugs Of The Year: New, Old, And Not-So-Funny at Forbes
12:16PM  Merck buys Swiss biotech with promising cancer drug AP
08:47AM  [$$] Merck Acquires OncoEthix for Up to $375 Million at The Wall Street Journal
07:30AM  Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers Business Wire
07:14AM  Call buyers take a dose of Merck optionMONSTER
05:45AM  Options Traders Buy the Pullback in Pharmaceuticals Giant Merck at TheStreet
Dec-15-14 04:01PM  The 4 Stocks That Weighed on Mondays Market at 24/7 Wall St.
02:10PM  Business events scheduled for Tuesday AP
11:00AM  Mosquito-Borne Dengue Targeted by Antibody With Hope for Vaccine at Bloomberg
08:24AM  The Zacks Analyst Blog Highlights: Chevron, Statoil, Merck, Boeing and General Electric Zacks
Dec-13-14 01:04PM  MERCK & CO., INC. Financials EDGAR Online Financials
Dec-12-14 11:54AM  Merck KGaA -- Moody's downgrades Merck KGaA's ratings to Baa1; negative outlook at Moody's
05:29AM  India caps prices of 52 more "essential" drugs - pricing authority Reuters
Dec-11-14 04:10PM  Merck Reveals Data from Breast Cancer Study on Keytruda Zacks
03:28PM  Experimental Trial of Merck Ebola Vaccine Suspended at The Wall Street Journal
02:25PM  Lilly Upgraded On 2 Potential Blockbuster Drugs at Investor's Business Daily
02:17PM  Human trial of experimental Merck Ebola vaccine is suspended at MarketWatch
12:14PM  [video]Merck Buys Cubist, Amazon's Auction Alternative & Cheerios New Flavor at TheStreet
11:59AM  Merck suspends trial of Ebola vaccine at Financial Times
11:33AM  Ebola vaccine trial halted temporarily after joint pains -Geneva hospital Reuters
11:27AM  Celgene's Abraxane Succeeds In Early Breast Cancer at Investor's Business Daily
10:29AM  $300 mln pledged to buy Ebola vaccines as NewLink shot hits snag Reuters
08:01AM  Gilead Is Growing Fast And Its Stock Is Cheap at
02:00AM  One shot or two? Many questions unresolved in Ebola vaccine race Reuters
12:12AM  FDA Clears New Version of Mercks Gardasil at The Wall Street Journal
Dec-10-14 05:04PM  FDA Clears New Version of Merck's Gardasil at The Wall Street Journal
04:09PM  New HPV vaccine strengthens cancer protection AP
03:30PM  Merck-Cubist Deal On Despite Patent Setback, Shares Fall Zacks
02:57PM  Merck advancing breast cancer drug to mid-stage AP
11:04AM  Merck's Keytruda Might Treat Virulent Breast Cancer at Investor's Business Daily
09:44AM  Merck's $8.4 Billion Deal for Cubist Looks $2 Billion Too Expensive Now at The Wall Street Journal
09:30AM  Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health Business Wire
09:21AM  Merck Checkpoint Inhibitor Shows Activity in Hard-to-Treat Form of Breast Cancer at TheStreet
08:57AM  Merck drug shrank tumors in some breast cancer patients in trial at MarketWatch
08:45AM  International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer Business Wire
08:30AM  Merck Drug Shrank Tumors in Some Breast Cancer Patients at The Wall Street Journal
08:30AM  Data Investigating KEYTRUDA┬« (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium Business Wire
01:28AM  Merck Reaffirms Commitment to Cubist Deal Amid Criticism on Patent Ruling at The Wall Street Journal
Dec-09-14 09:31PM  Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests PR Newswire
06:52PM  Cubist sales force seen as potential boon for Merck intestinal drug Reuters
06:00PM  Cramer views market like NFL CNBC
04:49PM  Merck Reaffirms Commitment to Cubist Deal at The Wall Street Journal
04:43PM  Merck and Spirit Airlines are big market movers AP
03:30PM  Cubist Shoots Up on $9.5 Billion Buyout Offer from Merck Zacks
03:02PM  Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Benzinga
12:14PM  Mizuho Securities Downgrades Cubist Pharmaceuticals Post Acquisition Announcement Benzinga
11:27AM  Merck-Cubist Deal Is On Despite Patent Setback at Investor's Business Daily
11:17AM  Merck & Cubist: Well, It Seemed Like a Good Idea at the Time at
11:09AM  Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals Inc Benzinga
10:59AM  Jim Cramer on the Stock Market: Thoughts on Merck's Deal for Cubist at TheStreet
10:52AM  What Does Merck do Now That Cubist Lost a Key Patent Ruling? at The Wall Street Journal
10:38AM  Stocks Swoon In Heavy Trade; Spirit Airlines Spirals Lower at Investor's Business Daily
10:27AM  Merck committed to Cubist after patent losses AP
09:35AM  Merck says still plans to buy Cubist, despite patent setback Reuters
09:30AM  Merck & Co. Under Pressure Following Patent Ruling Benzinga
09:27AM  Stocks to Watch: Conn's, AutoZone, Abercrombie & Fitch at The Wall Street Journal
08:59AM  Merck says still plans Cubist purchase, despite patent setback Reuters
08:50AM  After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired? at 24/7 Wall St.
08:30AM  Michigans Gordon, Bloombergs McCracken on Merck Deal (Audio) at Bloomberg
08:11AM  Merck Statement Regarding CUBICIN Patent Litigation Business Wire
07:45AM  Biotech ETFs in Focus on Cubist Takeover Deal Zacks
06:00AM  Jim Cramer's Top Stock Picks: DIS SBUX NKE ENB MRK CRZO at TheStreet
12:29AM  Merck to Buy Antibiotics Maker for $8.4 Billion at The Wall Street Journal
Dec-08-14 10:42PM  Asian stocks fall on growth concerns AP
09:46PM  Merck to Buy Cubist for $8.4 Billion at The Wall Street Journal
06:49PM  Antibiotics Worth A Shot: Merck To Purchase Cubist Investor's Business Daily
06:48PM  Cramer's personal connection to Merck acquisition at CNBC
06:44PM  Merck to take on superbugs with Cubist Pharma buy Reuters
06:30PM  Merck dives into 'superbug' chase with Cubist AP
06:09PM  Merck to buy Cubist Pharmaceuticals for $8.4 billion at Los Angeles Times
05:10PM  Merck's $9.5B Purchase Of Cubist Likely a Winner at
05:09PM  Merck Announces Acquisition of Cubist; Hedge Funds Celebrate Yahoo Finance Blogs
04:49PM  US STOCKS-S&P 500 posts worst day since Oct; energy shares sink Reuters
04:41PM  McDonald's and Sony are big market movers AP
04:17PM  Stocks tumble as oil prices plunge 4% at USA TODAY
03:17PM  Why Jim Cramer Likes Merck's Acquisition of Cubist Pharmaceuticals (CBST) at TheStreet
02:56PM  US STOCKS-Wall St drops with energy shares; global data disappoints Reuters
02:56PM  [video]Merck Seeks Growth Injection, Picks Off Antibiotic Maker Cubist at TheStreet
02:46PM  Merck Triggers The Race to Replace Cubist at Forbes
02:23PM  US stocks fall in afternoon as energy shares tank AP
02:16PM  Merck & Co., Inc. -- Moody's affirms Merck & Co.'s ratings; outlook stable at Moody's
02:10PM  Merck's New Oncology Product Positive in Early Study Zacks
02:05PM  Merck buying Cubist Pharmaceuticals for $8.4B at USA TODAY
01:46PM  US STOCKS-Wall St falls with energy shares; global data disappoints Reuters
01:37PM  Two Cancer Drugs for Hodgkin Lymphoma Shown Effective at The Wall Street Journal
01:23PM  Merck/Cubist: pony up at Financial Times
01:01PM  $9.5 billion blockbuster drug deal CNBC
12:44PM  Superbug threat drives $9.5bn Merck deal at Financial Times
11:48AM  Merck Acquiring Cubist, Focusing On Hospital Care at Investor's Business Daily
11:36AM  Merck to Buy Cubist Pharmaceuticals in $9.5 Billion Deal at TheStreet
11:26AM  Best Biotech ETFs Gets a Lift From Mercks Cubist Buy ETF Trends
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company's Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 04Option Exercise0.0019,147019,147May 06 04:03 PM
Golestani ClarkEVP & Chief Info OfficerMay 04Option Exercise0.002,05109,278May 06 04:02 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 04Option Exercise0.009,300098,387May 06 04:02 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareMay 04Option Exercise0.005,470038,311May 06 04:02 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.004,240011,999May 06 04:02 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise0.009,8470132,660May 06 04:02 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 04Option Exercise0.004,103026,720May 06 04:02 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 04Option Exercise0.004,103020,828May 06 04:01 PM
Deese Willie AExe V-P & Pres. MMDMay 04Option Exercise0.007,6590109,671May 06 04:01 PM
FRAZIER KENNETH CChairman, President & CEOMay 04Option Exercise0.0041,0280351,522May 06 04:01 PM
HARRISON WILLIAM B JRDirectorApr 25Option Exercise47.235,000236,1506,400Apr 29 11:36 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Option Exercise34.2012,876440,307320,541Apr 11 09:53 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Sale57.2410,047575,108310,494Apr 11 09:53 AM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Option Exercise39.90145,2255,794,929267,070Apr 04 05:07 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Sale56.43145,2258,195,164121,845Apr 04 05:07 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Option Exercise48.246,375307,53012,036Feb 14 05:11 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Sale55.475,990332,2766,046Feb 14 05:11 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Option Exercise36.5649,7501,818,86071,457Feb 14 11:17 AM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Sale55.0443,8702,414,57027,587Feb 14 11:17 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Option Exercise48.2410,000482,40020,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Option Exercise48.2445,0002,170,800304,349Feb 11 05:34 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Option Exercise47.6518,000857,70518,000Feb 13 10:12 AM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Sale55.6118,0001,000,9350Feb 13 10:12 AM
FRAZIER KENNETH CChairman, President & CEOFeb 11Sale54.5241,5202,263,683262,829Feb 11 05:34 PM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Sale55.7010,000557,00210,697Feb 11 05:07 PM
WENDELL PETER CDirectorFeb 10Option Exercise47.235,000236,1506,000Feb 11 03:48 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Option Exercise48.2420,000964,800156,049Feb 11 03:54 PM
WEEKS WENDELL PDirectorFeb 10Option Exercise47.235,000236,1505,100Feb 11 03:41 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Sale54.6850,0002,734,155106,049Feb 11 03:54 PM
WENDELL PETER CDirectorFeb 10Sale54.445,000272,1931,000Feb 11 03:48 PM
WEEKS WENDELL PDirectorFeb 10Sale54.265,000271,283100Feb 11 03:41 PM
Deese Willie AExe V-P & Pres. MMDJan 27Option Exercise47.7930,0001,433,700136,049Jan 28 10:09 AM